G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Granulocyte colony-stimulating factor (G-CSF) is upregulated in various tumors and influences neutrophil behavior.
• Myeloid-derived suppressor cells (MDSCs) are key players in tumor immune evasion and neoplastic progression.
• The specific role of G-CSF in regulating MDSCs and its impact on colitis-associated cancer (CAC) requires further elucidation.

Purpose of the Study:

• To investigate the mechanism by which G-CSF regulates MDSCs in a mouse model of colitis-associated cancer.
• To evaluate the therapeutic potential of targeting G-CSF to inhibit tumor growth in CAC.

Main Methods:

• Utilized a mouse model of colitis-associated cancer (CAC) to observe G-CSF and MDSC levels.
• Conducted in vitro studies to determine G-CSF's effect on MDSC survival and activation via the STAT3 pathway.
• Administered anti-G-CSF monoclonal antibody (mAb) to assess its impact on MDSC accumulation and tumor progression.

Main Results:

• Observed significant G-CSF overexpression and concomitant MDSC accumulation in mouse colon tissues within the CAC model.
• Demonstrated that G-CSF promotes MDSC survival and activation through the signal transducer and activator of transcription 3 (STAT3) signaling pathway.
• Anti-G-CSF mAb treatment led to decreased MDSC accumulation and a significant reduction in neoplasm size and number compared to isotype controls.

Conclusions:

• G-CSF is a critical regulator of myeloid-derived suppressor cell migration, proliferation, and function maintenance in colitis-associated cancer.
• Targeting G-CSF represents a promising therapeutic strategy for managing colitis-associated cancer by modulating MDSCs.